Provided by Tiger Fintech (Singapore) Pte. Ltd.

Regeneron Pharmaceuticals

704.31
+10.811.56%
Post-market: 705.000.6900+0.10%19:59 EST
Volume:1.13M
Turnover:799.25M
Market Cap:74.02B
PE:16.93
High:711.88
Open:693.34
Low:692.29
Close:693.50
52wk High:800.99
52wk Low:476.49
Shares:105.10M
Float Shares:103.30M
Volume Ratio:1.04
T/O Rate:1.10%
Dividend:2.64
Dividend Rate:0.37%
EPS(TTM):41.59
EPS(LYR):40.90
ROE:15.19%
ROA:6.16%
PB:2.39
PE(LYR):17.22

Loading ...

Sanofi And Regeneron's Dupixent Meets Endpoints, Accepted For Priority Review By FDA

Reuters
·
Nov 07

BRIEF-Dupixent (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

Reuters
·
Nov 07

FDA Accepts Priority Review for Sanofi and Regeneron’s Dupixent in Allergic Fungal Rhinosinusitis

Reuters
·
Nov 07

Regeneron Reports Dupixent Meets All Endpoints in Phase 3 Trial for Allergic Fungal Rhinosinusitis

Reuters
·
Nov 07

CommuniquÉ De Presse : Acaai : L’ÉTude Pivot Dupixent MenÉE Par Sanofi Et Regeneron a Atteint L’ensemble De Ses CritÈRes D’ÉValuation Principaux Et Secondaires, RÉDuisant Les Signes Et SymptÔMes De La Rhinosinusite Fongique Allergique...

THOMSON REUTERS
·
Nov 07

Dupixent® (Dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (Afrs); Sbla Accepted for FDA Priority Review

THOMSON REUTERS
·
Nov 07

Regeneron Pharmaceuticals Inc: Dupixent Sbla Accepted for Priority Review by U.S. FDA With a Target Action Date of February 28, 2026

THOMSON REUTERS
·
Nov 07

Regeneron price target raised to $660 from $595 at UBS

TIPRANKS
·
Nov 07

Regeneron Pharmaceuticals Inc. Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

Dow Jones
·
Nov 06

Is Regeneron a Value Opportunity After Fresh FDA Approvals and 24% Price Drop?

Simply Wall St.
·
Nov 05

Regeneron Pharmaceuticals Inc. Stock Underperforms Monday When Compared To Competitors

Dow Jones
·
Nov 04

Weekly Winners | Teradyne Spikes 26%; Western Digital Surges 16%; Regeneron Rallies 13%; First Solar Jumps 10%; Seagate Rises 9%

Tiger Newspress
·
Nov 02

Regeneron Director Christine A. Poon Reports Disposal of Common Shares

Reuters
·
Nov 01

Rothschild & Co Redburn Adjusts Price Target on Regeneron Pharmaceuticals to $910 From $900

MT Newswires Live
·
Nov 01

Dupixent® (dupilumab) Wins Prestigious 2025 Prix Galien USA Best Biotechnology Product Award

GlobeNewswire
·
Oct 31

'Sometimes the only winning move is not to play,' says Michael Burry in bubble warning

Dow Jones
·
Oct 31

Regeneron Pharmaceuticals Inc. Publishes Transcript of Q3 2025 Earnings Conference Call

Reuters
·
Oct 31

JW Cayman Therapeutics Signs Amendment to Collaboration Agreement with Regeneron

Reuters
·
Oct 30

Evercore ISI Remains a Buy on Regeneron (REGN)

TIPRANKS
·
Oct 30

Healthcare firm OPKO's Q3 revenue falls

Reuters
·
Oct 30